{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T10:58:58Z","timestamp":1785581938394,"version":"3.56.0"},"reference-count":7,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","license":[{"start":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T00:00:00Z","timestamp":1757980800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:p>Lymphangioleiomyomatosis (LAM) is a rare cystic lung disease primarily affecting women, driven by TSC1 or TSC2 mutations that lead to constitutive mTORC1 activation and progressive respiratory failure. While rapamycin remains the only approved treatment, it is disease-stabilizing rather than disease-reversing. Recent studies demonstrate that lung-targeted lipid nanoparticles delivering functional TSC2 mRNA can restore tumor suppressor activity, inhibit mTORC1 signaling, and reduce cystic lung damage in preclinical models, offering a potential disease-modifying approach. Effective nanomedicine delivery to LAM lungs faces significant barriers, including mucus entrapment, altered airflow, and fibrotic remodeling, necessitating mucus-penetrating formulations for uniform deposition. Advances in nanoparticle-based anti-fibrotic therapy from related conditions such as liver fibrosis support the translational promise of this approach. Clinical trials are urgently needed to optimize design, evaluate safety, and assess efficacy in patients with LAM, with the goal of achieving targeted, durable, and personalized therapy.<\/jats:p>","DOI":"10.1097\/ms9.0000000000003889","type":"journal-article","created":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T20:00:15Z","timestamp":1758225615000},"page":"7801-7802","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Nanomedicine for lymphangioleiomyomatosis: toward targeted and durable anti-fibrotic therapy"],"prefix":"10.1097","volume":"87","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-2598-1804","authenticated-orcid":false,"given":"Ashish Ashok","family":"Lal","sequence":"first","affiliation":[{"name":"Department of Medicine, Jinnah Sindh Medical University, Karachi, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7112-6865","authenticated-orcid":false,"given":"Muneeb","family":"Faiz","sequence":"additional","affiliation":[{"name":"Department of Medicine, King Edward Medical University, Lahore, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3413-2752","authenticated-orcid":false,"given":"Maliha","family":"Khalid","sequence":"additional","affiliation":[{"name":"Department of Medicine, Jinnah Sindh Medical University, Karachi, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Talha","sequence":"additional","affiliation":[{"name":"Department of Medicine, King Edward Medical University, Lahore, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3283-1982","authenticated-orcid":false,"given":"Aminath","family":"Waafira","sequence":"additional","affiliation":[{"name":"School of Medicine, The Maldives National University, Mal\u00e9, Maldives"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,9,16]]},"reference":[{"key":"R1-20260801","doi-asserted-by":"crossref","first-page":"1859\u201372","DOI":"10.1007\/s13346-021-01102-5","article-title":"Development of a novel rapamycin loaded nano- into micro-formulation for treatment of lung inflammation","volume":"12","author":"Craparo","year":"2022","journal-title":"Drug Deliv Transl Res"},{"key":"R2-20260801","doi-asserted-by":"crossref","first-page":"e2116271119","DOI":"10.1073\/pnas.2116271119","article-title":"Lung-selective mRNA delivery of synthetic lipid nanoparticles for the treatment of pulmonary lymphangioleiomyomatosis","volume":"119","author":"Qiu","year":"2022","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R3-20260801","doi-asserted-by":"crossref","first-page":"2","DOI":"10.5339\/gcsp.2015.2","article-title":"Inhaled nano- and microparticles for drug delivery","volume":"2015","author":"El-Sherbiny","year":"2015","journal-title":"Glob Cardiol Sci Pract"},{"key":"R4-20260801","doi-asserted-by":"crossref","first-page":"e1601556","DOI":"10.1126\/sciadv.1601556","article-title":"Nanoparticles that do not adhere to mucus provide uniform and long-lasting drug delivery to airways following inhalation","volume":"3","author":"Schneider","year":"2017","journal-title":"Sci Adv"},{"key":"R5-20260801","doi-asserted-by":"crossref","first-page":"9641\u201365","DOI":"10.2147\/IJN.S524078","article-title":"Nanomedicines in the treatment of liver fibrosis: a review","volume":"20","author":"Du","year":"2025","journal-title":"Ijn"},{"key":"R6-20260801","doi-asserted-by":"crossref","first-page":"6997\u20137006","DOI":"10.2147\/IJN.S145951","article-title":"Nanoparticles for the treatment of liver fibrosis","volume":"12","author":"Poilil Surendran","year":"2017","journal-title":"Int J Nanomedicine"},{"key":"R7-20260801","first-page":"100082","article-title":"Transparency In The reporting of Artificial INtelligence \u2013 the TITAN guideline","volume":"10","author":"Agha","year":"2025","journal-title":"Prem J Sci"}],"container-title":["Annals of Medicine &amp; Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MS9.0000000000003889","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T10:10:59Z","timestamp":1785579059000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MS9.0000000000003889"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,16]]},"references-count":7,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/ms9.0000000000003889","relation":{},"ISSN":["2049-0801"],"issn-type":[{"value":"2049-0801","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,16]]},"assertion":[{"value":"2025-08-25","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-30","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}